Primary Cutaneous Aspergillosis in an Immunocompetent Patient: Successful Treatment with Oral Voriconazole
暂无分享,去创建一个
[1] E. Lane,et al. A spectrum of mutations in keratins K6a, K16 and K17 causing pachyonychia congenita. , 2007, Journal of dermatological science.
[2] A. Mejias,et al. Successful medical treatment of cutaneous aspergillosis in a premature infant using liposomal amphotericin B, voriconazole and micafungin. , 2007, The Pediatric infectious disease journal.
[3] F. Eifinger,et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight , 2006, Journal of Perinatology.
[4] E. Lane,et al. Clinical and pathological features of pachyonychia congenita. , 2005, The journal of investigative dermatology. Symposium proceedings.
[5] A. Hebert,et al. Neonatal Primary Cutaneous Aspergillosis: Case Report and Review of the Literature , 2002, Pediatric dermatology.
[6] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[7] J. Perfect,et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children , 2002, The Pediatric infectious disease journal.
[8] R. Jones,et al. Outbreak of primary cutaneous aspergillosis related to intravenous arm boards. , 1986, The Journal of pediatrics.